These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Cytokeratin 8/18-negative somatotroph pituitary neuroendocrine tumours (PitNETs, adenomas) show variable morphological features and do not represent a clinicopathologically distinct entity. Soukup J; Cesak T; Hornychova H; Manethova M; Michnova L; Netuka D; Vitovcova B; Cap J; Ryska A; Gabalec F Histopathology; 2021 Sep; 79(3):406-415. PubMed ID: 33738859 [TBL] [Abstract][Full Text] [Related]
11. Functional characterization of DLK1/MEG3 locus on chromosome 14q32.2 reveals the differentiation of pituitary neuroendocrine tumors. Chen Y; Gao H; Liu Q; Xie W; Li B; Cheng S; Guo J; Fang Q; Zhu H; Wang Z; Wang J; Li C; Zhang Y Aging (Albany NY); 2020 Dec; 13(1):1422-1439. PubMed ID: 33472171 [TBL] [Abstract][Full Text] [Related]
12. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1. Asa SL; Mete O; Riddle ND; Perry A Endocr Pathol; 2023 Sep; 34(3):273-278. PubMed ID: 37268858 [TBL] [Abstract][Full Text] [Related]
13. Production of alpha-subunit of glycoprotein hormones by pituitary somatotroph adenomas in vitro. Kontogeorgos G; Asa SL; Kovacs K; Smyth HS; Singer W Acta Endocrinol (Copenh); 1993 Dec; 129(6):565-72. PubMed ID: 7509101 [TBL] [Abstract][Full Text] [Related]
14. Clinical and Proteomic-Based Molecular Characterizations of Invasive and Noninvasive Somatotroph PitNETs. Chen M; Duan L; Sun W; Guo Z; Miao H; Yu N; Yang S; Wang L; Gong F; Yao Y; Zhu H Neuroendocrinology; 2023; 113(9):971-986. PubMed ID: 37253344 [TBL] [Abstract][Full Text] [Related]
15. Differential gene expression and pathway analysis in growth hormone-secreting pituitary tumors according to granulation pattern. Kim K; Kim Y; Kim SH; Moon JH; Kim EH; Lee EJ; Oh CM; Ku CR Front Oncol; 2024; 14():1423606. PubMed ID: 39139281 [TBL] [Abstract][Full Text] [Related]
16. Pangenomic Classification of Pituitary Neuroendocrine Tumors. Neou M; Villa C; Armignacco R; Jouinot A; Raffin-Sanson ML; Septier A; Letourneur F; Diry S; Diedisheim M; Izac B; Gaspar C; Perlemoine K; Verjus V; Bernier M; Boulin A; Emile JF; Bertagna X; Jaffrezic F; Laloe D; Baussart B; Bertherat J; Gaillard S; Assié G Cancer Cell; 2020 Jan; 37(1):123-134.e5. PubMed ID: 31883967 [TBL] [Abstract][Full Text] [Related]
17. Transcriptomic analysis identifies a tumor subtype mRNA classifier for invasive non-functioning pituitary neuroendocrine tumor diagnostics. Bao X; Wang G; Yu S; Sun J; He L; Zhao H; Ma Y; Wang F; Wang X; Wang R; Yu J Theranostics; 2021; 11(1):132-146. PubMed ID: 33391466 [No Abstract] [Full Text] [Related]
18. Is Somatostatin Receptor and Dopamine Receptor profiling useful in the management of silent somatotroph tumors? Martínez-López S; García-Martínez A; Torregrosa-Quesada ME; López-Muñoz B; Cámara R; Fajardo C; Lamas C; Picó A J Endocrinol Invest; 2020 Jun; 43(6):859-863. PubMed ID: 31898311 [TBL] [Abstract][Full Text] [Related]
19. Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas. Mayr B; Buslei R; Theodoropoulou M; Stalla GK; Buchfelder M; Schöfl C Eur J Endocrinol; 2013 Oct; 169(4):391-400. PubMed ID: 23847328 [TBL] [Abstract][Full Text] [Related]
20. MiR-320a Acts as a Tumor Suppressor in Somatotroph Pituitary Neuroendocrine Tumors by Targeting BCAT1. Zhao S; Li B; Gao H; Zhang Y Neuroendocrinology; 2024; 114(1):14-24. PubMed ID: 37591221 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]